Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Diabetes
•
Endocrinology
What is the recommended approach to treating severe constipation in patients on GLP1 R agonist therapy?
Related Questions
Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?
How do you interpret the presence of GAD antibody in a middle-aged patient with diabetes when all other type 1 diabetes antibodies are absent?
Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
When should metformin be stopped before surgery and when is it considered safe to resume?
Do patients with advanced chronic kidney disease tend to have falsely high HbA1c or falsely low HbA1c levels?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
Under what circumstances would you test for hypercortisolism in a patient with insulin resistance?
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
